HFMedChoice.com: Heart Failure Medical Therapy Decision Tool for Healthcare Providers

Step 1: Assess current risk

MAGGIC

Risk of death at 1 & 3 years
BCN Bio-HF

Risk of death & HF hospitalization at 1-5 years

Demographics

Age

years

Sex

Male Female

Weight

Height

BMI

HF Information

HF Duration

months

NHYA Class

1 2 3 4

Ejection Fraction

HF hospitalizations (within last 12 months)

Medical History & Labs

Diabetes

Yes No

Current smoker

Yes No

COPD

Yes No

Systolic BP

mmHg

Serum creatinine

umol/L

NT-proBNP

ng/L

No NT-proBNP available

Serum sodium

mmol/L

Hemoglobin

g/L

eGFR

mL/min/1.73 m²

Step 2: Select drug therapy options

Cumulative relative benefit:

ACE-I/ARB (below target dose)

ACE-I/ARB (target dose)

Sacubitril-valsartan

Beta blocker

Spironolactone/eplerenone

SGLT2 inhibitor (e.g. dapagliflozin, empagliflozin)

Digoxin

Fish oil (omega-3 FA)

Hydralazine-nitrate

(in black patients; see FAQ)

Ivabradine

Vericiguat

Step 3: Estimated benefits & harms

Endpoint:	Mortality HF hospitalization The MAGGIC risk score only estimates mortality at 1 and 3 years
Time period:	1 2 3 4 5 year(s)
Note for EMR Share/Save Use the following link to save or share the current de-identified patient information and selected treatments: https://... Link copied to clipboard

Risk of dying within 1 year:

Current

N/A

With Therapy

N/A

No Event	Treatment Benefit	Event

Possible Side Effects

Displayed percentages represent the absolute risk increase compared to placebo (except for sacubitril-valsartan, which was compared to ACE inhibitor). Only differences found to be statistically significant in randomized controlled trials are shown.

No treatment selected

Other Treatment Information

No treatment selected

Welcome to HFMedChoice.com

This tool is intended to assist clinicians and their patients in discussions on the potential benefits and harms of medical therapies for heart failure (HF).